SOURCE: Boston Therapeutics

Boston Therapeutics

November 18, 2013 07:38 ET

Boston Therapeutics Presents at the Elsevier Therapeutic Area Partnerships 2013 Conference in Boston on November 19

Company Chosen as One of 10 "Top Projects to Watch" in Area of Cardiovascular/Metabolic Diseases

MANCHESTER, NH--(Marketwired - Nov 18, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, will be presenting at the Elsevier Therapeutic Area Partnerships ("TAP") 2013 Conference at The Hyatt Regency in Boston on Tuesday, November 19 from 2:15 pm to 3:05 pm ET within Track 4 (Cardiovascular/Metabolic Diseases).

Kenneth A. Tassey, Jr., President of Boston Therapeutics, will present information about PAZ320, an investigational non-systemic chewable tablet that when taken as an adjunctive therapy helped 45% of the patients with Type II diabetes manage the post-meal elevation of their blood sugar in a Phase IIa clinical trial.

For the conference, Boston Therapeutics was chosen as one of 10 "Top Projects to Watch" within the area of cardiovascular/metabolic diseases. These are handpicked by a panel of independent experts who screen hundreds of compounds and weigh their potential as future products. The criteria were: large market, large unmet need, with increasing opportunity; history of the molecule and drug; strong science; strong company; diversity of indications; potential for new opportunities beyond the initial indications; and multilevel partnering opportunities.

Mr. Tassey said, "TAP 2013 promises to be one of the key meetings of the year within the cardiovascular/metabolic disease area. We are pleased with this opportunity to educate attendees about the potential benefits of PAZ320, and are honored to be named a 'Top Project to Watch' by the independent panel."

About the Therapeutic Area Partnerships Conference

Since its launch eight years ago, Therapeutic Area Partnerships (TAP) has come to be regarded as the industry's premier biopharmaceutical partnering event and a meeting for the sharpest minds in biopharma. A uniquely efficient gathering, TAP brings together decision-makers to assess the most promising drug programs available for partnering in oncology, cardiovascular/metabolic diseases, neuroscience, infectious diseases, anti-inflammatory/autoimmune diseases and advanced therapies. Attendees have the opportunity to hear from and meet some of the industry's most talented biotechnology entrepreneurs and pharmaceutical leaders. Casual gatherings and one-on-one partnering meetings bring together business development decision makers from large pharmaceutical firms and executive leadership from innovative biotechnology firms to make this one of the industry's most productive events. More information is available at www.elsevierbi.com/mkt/Conf/TAP2013/TAP2013.

About PAZ320

PAZ320 is a non-systemic chewable complex carbohydrate-based compound designed to reduce post-meal elevation of blood glucose. PAZ320 is a proprietary polysaccharide designed to be taken before meals and works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down carbohydrates into glucose and release it into the bloodstream.

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is an innovator in designing drugs using complex carbohydrate chemistry. The Company's product pipeline is focused on developing and commercializing therapeutic molecules that address Type 2 diabetes, including: PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug specifically designed to treat lower limb ischemia associated with diabetes. More information is available at www.bostonti.com.

Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of our drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in the trials could delay obtaining meaningful results from Phase II and/or preparing for Phase III with the current cash on hand.

Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from this proposed indication. Plans regarding development, approval and marketing of any of our drugs, including PAZ320, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2012, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Contact Information